273 selected records with a cited source date in 2024, shown 200 per page, newest first. This archive is selective and does not imply continuous monitoring or complete historical coverage.
PeptideScanner retained ClinicalTrials.gov record NCT05326776 at 2026-11-16T00:59:19.138Z. Its registry update date was 2024-12-31, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT06677502 at 2026-11-16T17:33:14.861Z. Its registry update date was 2024-12-31, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PubMed lists PMID 38606836 in Journal of chemotherapy (Florence, Italy) as Journal Article, Review, Case Reports, with publication-date metadata of 2024-04-12 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 6 for the reviewed Teriparatide label family with a published date of 2024-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 14 for the reviewed Tirzepatide label family with a published date of 2024-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PubMed lists PMID 39549717 in The lancet. Diabetes & endocrinology as Journal Article, with publication-date metadata of 2024-11-13 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 7 for the reviewed Tesamorelin label family with a published date of 2024-12-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 215503 with status AP dated 2024-12-23, and names liraglutide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 15 for the reviewed Vosoritide label family with a published date of 2024-12-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PubMed lists PMID 22231041 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2012-01-09 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 22322237 in Journal of hepatology as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2012-02-06 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 39648386 in Journal of the College of Physicians and Surgeons--Pakistan : JCPSP as Systematic Review, Journal Article, Meta-Analysis, with publication-date metadata of 2024-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT02049034 at 2026-07-30T18:37:14.684Z. Its registry update date was 2024-12-16, and PeptideScanner's reviewed identity mapping was lixisenatide.
PubMed lists PMID 39669625 in Genetics in medicine open as Journal Article, with publication-date metadata of 2024-06-22 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 16 for the reviewed Leuprolide label family with a published date of 2024-12-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PubMed lists PMID 39596113 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2024-11-09 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 10 for the reviewed Semaglutide label family with a published date of 2024-12-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 204468 with status AP dated 2024-12-12, and names glucagon among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT06234111 at 2026-07-30T18:37:14.697Z. Its registry update date was 2024-12-12, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04775953 at 2026-11-15T22:01:45.056Z. Its registry update date was 2024-12-10, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT01950403 at 2026-07-30T18:37:14.701Z. Its registry update date was 2024-12-09, and PeptideScanner's reviewed identity mapping was linaclotide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 212675 with status AP dated 2024-12-05, and names calcitonin salmon among the application record's active ingredients.
PubMed lists PMID 39618221 in British journal of hospital medicine (London, England : 2005) as Journal Article, Review, with publication-date metadata of 2024-11-25 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT06629688 at 2026-07-30T18:37:14.696Z. Its registry update date was 2024-12-05, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02685397 at 2026-07-30T18:37:14.689Z. Its registry update date was 2024-12-04, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT05912621 at 2026-07-30T18:37:14.695Z. Its registry update date was 2024-12-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06091436 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-12-03, and PeptideScanner's reviewed identity mapping was ganirelix.
PubMed lists PMID 39334129 in BMC medicine as Journal Article, Randomized Controlled Trial, Comparative Study, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-09-27 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38560548 in Hospital pharmacy as Journal Article, Review, with publication-date metadata of 2023-01-26 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 2 for the reviewed Lanreotide label family with a published date of 2024-12-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT04627025 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-11-27, and PeptideScanner's reviewed identity mapping was apraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04966741 at 2026-07-30T18:38:25.516Z. Its registry update date was 2024-11-27, and PeptideScanner's reviewed identity mapping was setmelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT03035032 at 2026-07-30T18:38:25.519Z. Its registry update date was 2024-11-26, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT03965130 at 2026-07-30T18:38:25.510Z. Its registry update date was 2024-11-26, and PeptideScanner's reviewed identity mapping was glucagon.
PubMed lists PMID 38967895 in The international journal of cardiovascular imaging as Journal Article, Validation Study, Comparative Study, with publication-date metadata of 2024-07-05 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 11 for the reviewed Exenatide label family with a published date of 2024-11-25. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT02366494 at 2026-07-30T18:38:25.510Z. Its registry update date was 2024-11-25, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT04991311 at 2026-11-16T01:46:56.290Z. Its registry update date was 2024-11-22, and PeptideScanner's reviewed identity mapping was glepaglutide.
The official Drugs@FDA dataset lists original submission 1 for NDA 217630 with status AP dated 2024-11-21, and names daptomycin among the application record's active ingredients.
PubMed lists PMID 39526054 in TouchREVIEWS in endocrinology as Journal Article, Review, with publication-date metadata of 2024-02-09 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2024-27048, attributed to FDA and its parent HHS department, on 2024-11-20. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04883346 at 2026-07-30T18:38:25.517Z. Its registry update date was 2024-11-20, and PeptideScanner's reviewed identity mapping was liraglutide.
The Federal Register published notice 2024-26913, attributed to FDA and its parent HHS department, on 2024-11-19. Its official title is “Pfizer, Inc., et al.; Withdrawal of Approval of 26 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 206697 with status AP dated 2024-11-19, and names exenatide synthetic among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 6 for the reviewed Leuprolide label family with a published date of 2024-11-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PubMed lists PMID 39519595 in Nutrients as Journal Article, with publication-date metadata of 2024-11-01 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 9 for the reviewed Semaglutide label family with a published date of 2024-11-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 54 for the reviewed Dulaglutide label family with a published date of 2024-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 19 for the reviewed Lixisenatide label family with a published date of 2024-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 14 for the reviewed Vosoritide label family with a published date of 2024-11-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT04943068 at 2026-07-30T18:38:25.522Z. Its registry update date was 2024-11-13, and PeptideScanner's reviewed identity mapping was bremelanotide.
PubMed lists PMID 30013296 in P & T : a peer-reviewed journal for formulary management as Journal Article, with publication-date metadata of 2018-07 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38811560 in Blood cancer journal as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-29 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 29719376 in Drug design, development and therapy as Journal Article, Review, with publication-date metadata of 2018-04-19 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38593241 in Blood advances as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-06-11 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 39126516 in Acta diabetologica as Journal Article, with publication-date metadata of 2024-08-10 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 12 for the reviewed Tirzepatide label family with a published date of 2024-11-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT05804162 at 2026-07-30T18:38:25.523Z. Its registry update date was 2024-11-01, and PeptideScanner's reviewed identity mapping was cagrilintide.
The Federal Register published notice 2024-25391, attributed to FDA and its parent HHS department, on 2024-10-31. Its official title is “Product-Specific Guidances; Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.
PubMed lists PMID 38318312 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2024-01-22 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38949062 in Biomacromolecules as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-07-01 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38629183 in Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners as Journal Article, Comparative Study, Review, with publication-date metadata of 2024-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 39469962 in Ginekologia polska as Journal Article, with publication-date metadata of 2023 (year precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT04699032 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-26, and PeptideScanner's reviewed identity mapping was apraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06002555 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-26, and PeptideScanner's reviewed identity mapping was apraglutide.
The Federal Register published notice 2024-24828, attributed to FDA and its parent HHS department, on 2024-10-25. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to CJC-1295.
PeptideScanner retained ClinicalTrials.gov record NCT05995704 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-24, and PeptideScanner's reviewed identity mapping was apraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02975999 at 2026-11-15T22:08:31.832Z. Its registry update date was 2024-10-24, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT06519656 at 2026-07-30T18:39:33.787Z. Its registry update date was 2024-10-24, and PeptideScanner's reviewed identity mapping was mazdutide.
PubMed lists PMID 37584290 in Haematologica as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-02-01 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT03471728 at 2026-07-30T18:39:33.779Z. Its registry update date was 2024-10-18, and PeptideScanner's reviewed identity mapping was linaclotide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 217957 with status AP dated 2024-10-17, and names leuprolide acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT05709444 at 2026-07-30T18:39:33.780Z. Its registry update date was 2024-10-17, and PeptideScanner's reviewed identity mapping was bremelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT02310269 at 2026-11-15T22:05:38.400Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT05767086 at 2026-11-15T22:02:39.332Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was cetrorelix.
PubMed lists PMID 39403865 in Expert review of medical devices as Journal Article, Validation Study, with publication-date metadata of 2024-10-15 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 39399714 in Translational pediatrics as Editorial, Comment, with publication-date metadata of 2024-09-11 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT05708859 at 2026-07-30T18:39:33.781Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was tirzepatide.
PubMed lists PMID 39386004 in Journal of pharmaceutical analysis as Journal Article, with publication-date metadata of 2024-07-02 (day precision). PeptideScanner associated the retained record with the identity slug ziconotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 29242099 in International journal of cardiology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2017-12-06 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 37862457 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2024-01-01 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT03839823 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-10-09, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT04460560 at 2026-11-15T21:47:40.408Z. Its registry update date was 2024-10-09, and PeptideScanner's reviewed identity mapping was terlipressin.
PubMed lists PMID 37460385 in Trends in pharmacological sciences as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-07-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT01794793 at 2026-11-15T22:05:38.400Z. Its registry update date was 2024-10-01, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT04216589 at 2026-07-30T18:39:33.783Z. Its registry update date was 2024-10-01, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05181800 at 2026-11-15T21:52:09.579Z. Its registry update date was 2024-09-27, and PeptideScanner's reviewed identity mapping was degarelix.
The official Drugs@FDA dataset lists original submission 1 for NDA 213224 with status AP dated 2024-09-27, and names octreotide acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 203857 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 206873 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients.
The Federal Register published notice 2024-21941, attributed to FDA and its parent HHS department, on 2024-09-25. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DAYBUE,” and PeptideScanner's exact reviewed identity mapping connects the document to Trofinetide.
PubMed lists PMID 37171185 in Acta biochimica et biophysica Sinica as Review, Journal Article, with publication-date metadata of 2023-05-12 (day precision). PeptideScanner associated the retained record with the identity slug peg-mgf. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213766 with status AP dated 2024-09-20, and names calcitonin salmon among the application record's active ingredients.
PubMed lists PMID 39295934 in Frontiers in pharmacology as Journal Article, Systematic Review, with publication-date metadata of 2024-09-04 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT02814916 at 2026-11-16T17:37:42.807Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was dalbavancin.
PeptideScanner retained ClinicalTrials.gov record NCT00703014 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT03935984 at 2026-11-15T21:54:02.201Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was calcitonin-salmon.
PubMed lists PMID 38453703 in Annals of hematology as Journal Article, Clinical Trial, with publication-date metadata of 2024-03-08 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 37223762 in F&S reports as Journal Article, with publication-date metadata of 2022-11-21 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2024-21241, attributed to FDA and its parent HHS department, on 2024-09-18. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List,” and PeptideScanner's exact reviewed identity mapping connects the document to Ipamorelin.
PubMed lists PMID 37106758 in Biology as Journal Article, Review, with publication-date metadata of 2023-04-06 (day precision). PeptideScanner associated the retained record with the identity slug humanin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38747414 in Polish archives of internal medicine as Journal Article, Clinical Trial, Phase III, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-14 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 39107738 in BMC endocrine disorders as Case Reports, Journal Article, Review, with publication-date metadata of 2024-08-06 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2024-20062, attributed to FDA and its parent HHS department, on 2024-09-06. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application 215244 for Elamipretide Hydrochloride Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Elamipretide.
PeptideScanner retained ClinicalTrials.gov record NCT00702273 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-05, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT00702520 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-09-05, and PeptideScanner's reviewed identity mapping was triptorelin.
PubMed lists PMID 36237613 in Frontiers in neurology as Journal Article, with publication-date metadata of 2022-09-27 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 39201278 in International journal of molecular sciences as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2024-08-06 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT06581679 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-09-03, and PeptideScanner's reviewed identity mapping was triptorelin.
PubMed lists PMID 39204186 in Pharmaceuticals (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2024-08-17 (day precision). PeptideScanner associated the retained record with the identity slug bpc-157. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 31710397 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2019-11-11 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 14 for the reviewed Leuprolide label family with a published date of 2024-08-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT03574597 at 2026-07-30T18:41:37.951Z. Its registry update date was 2024-08-30, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06099067 at 2026-07-30T18:41:37.931Z. Its registry update date was 2024-08-30, and PeptideScanner's reviewed identity mapping was liraglutide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 217215 with status AP dated 2024-08-29, and names daptomycin among the application record's active ingredients.
PubMed lists PMID 38996787 in Animal reproduction science as Journal Article, with publication-date metadata of 2024-07-05 (day precision). PeptideScanner associated the retained record with the identity slug ipamorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 39002910 in International journal of biological macromolecules as Journal Article, with publication-date metadata of 2024-07-11 (day precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 31820428 in Thrombosis and haemostasis as Comparative Study, Letter, Systematic Review, with publication-date metadata of 2019-12-09 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2024-18898, attributed to FDA and its parent HHS department, on 2024-08-23. Its official title is “Final Decision on the Proposal To Refuse To Approve a New Drug Application for ITCA 650,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Glucagon.
The Federal Register published notice 2024-18997, attributed to FDA and its parent HHS department, on 2024-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Teriparatide.
PubMed lists PMID 15668708 in British journal of cancer as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2005-02-14 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 18 for the reviewed Pramlintide label family with a published date of 2024-08-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PubMed lists PMID 34829776 in Biomedicines as Journal Article, with publication-date metadata of 2021-10-27 (day precision). PeptideScanner associated the retained record with the identity slug bpc-157. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 37534517 in Haematologica as Clinical Trial, Phase II, Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-03-01 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 8 for the reviewed Afamelanotide label family with a published date of 2024-08-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT00988260 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-08-15, and PeptideScanner's reviewed identity mapping was ganirelix.
PubMed lists PMID 39129819 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2024-08-09 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT03859427 at 2026-11-16T17:39:29.005Z. Its registry update date was 2024-08-13, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT03036800 at 2026-07-30T18:41:37.923Z. Its registry update date was 2024-08-13, and PeptideScanner's reviewed identity mapping was liraglutide.
The official Drugs@FDA dataset lists original submission 1 for NDA 216490 with status AP dated 2024-08-09, and names palopegteriparatide among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT04179734 at 2026-07-30T18:41:37.916Z. Its registry update date was 2024-08-09, and PeptideScanner's reviewed identity mapping was bremelanotide.
PubMed lists PMID 27246172 in Advances in therapy as Journal Article, Review, with publication-date metadata of 2016-05-31 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 8 for the reviewed Tirzepatide label family with a published date of 2024-08-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2024-17649, attributed to FDA and its parent HHS department, on 2024-08-08. Its official title is “Determination That DELATESTRYL (Testosterone Enanthate) Injection, 200 Milligrams/Milliliter, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT06541509 at 2026-07-30T18:41:37.930Z. Its registry update date was 2024-08-07, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06208540 at 2026-11-16T17:33:14.861Z. Its registry update date was 2024-08-05, and PeptideScanner's reviewed identity mapping was cerebrolysin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213396 with status AP dated 2024-08-01, and names daptomycin among the application record's active ingredients.
PubMed lists PMID 32843370 in Clinical journal of the American Society of Nephrology : CJASN as Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-08-25 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 32096613 in Journal of cachexia, sarcopenia and muscle as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-02-25 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 32353679 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2020-03-27 (day precision). PeptideScanner associated the retained record with the identity slug bremelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 39072348 in Diabetes, metabolic syndrome and obesity : targets and therapy as Journal Article, Review, with publication-date metadata of 2024-07-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2024-16618, attributed to FDA and its parent HHS department, on 2024-07-29. Its official title is “Pediatric Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Teduglutide.
PubMed lists PMID 39062238 in Children (Basel, Switzerland) as Journal Article, with publication-date metadata of 2024-06-28 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 28480768 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2017-05-19 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 51 for the reviewed Dulaglutide label family with a published date of 2024-07-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT02403284 at 2026-07-30T18:42:56.623Z. Its registry update date was 2024-07-22, and PeptideScanner's reviewed identity mapping was liraglutide.
PubMed lists PMID 31687504 in Heliyon as Journal Article, Review, with publication-date metadata of 2019-10-23 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 39019866 in Cell discovery as Letter, with publication-date metadata of 2024-07-17 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 36840897 in GeroScience as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-02-25 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38869952 in Expert review of gastroenterology & hepatology as Journal Article, Review, with publication-date metadata of 2024-06-18 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38981105 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2024-07-08 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT03891875 at 2026-07-30T18:42:56.626Z. Its registry update date was 2024-07-12, and PeptideScanner's reviewed identity mapping was elamipretide.
PeptideScanner retained ClinicalTrials.gov record NCT06498063 at 2026-07-30T18:42:56.616Z. Its registry update date was 2024-07-12, and PeptideScanner's reviewed identity mapping was glucagon.
The official Drugs@FDA dataset lists original submission 1 for NDA 217766 with status AP dated 2024-07-11, and names vasopressin among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 34 for the reviewed Linaclotide label family with a published date of 2024-07-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT05151328 at 2026-07-30T18:42:56.581Z. Its registry update date was 2024-07-11, and PeptideScanner's reviewed identity mapping was plecanatide.
PeptideScanner retained ClinicalTrials.gov record NCT02400801 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-07-10, and PeptideScanner's reviewed identity mapping was triptorelin.
PubMed lists PMID 38982703 in Endocrine, metabolic & immune disorders drug targets as Journal Article, with publication-date metadata of 2024-07-05 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 17 for the reviewed Pramlintide label family with a published date of 2024-07-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 5 for the reviewed Teriparatide label family with a published date of 2024-07-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PubMed lists PMID 38933071 in World journal of nuclear medicine as Journal Article, with publication-date metadata of 2024-05-07 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT05242783 at 2026-11-15T21:47:40.408Z. Its registry update date was 2024-06-25, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT06473259 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-06-25, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT05849389 at 2026-07-30T18:43:56.187Z. Its registry update date was 2024-06-24, and PeptideScanner's reviewed identity mapping was vosoritide.
PubMed lists PMID 38903817 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2024-06-06 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00696800 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-06-20, and PeptideScanner's reviewed identity mapping was ganirelix.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213773 with status AP dated 2024-06-14, and names icatibant acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT04249232 at 2026-07-30T18:43:56.172Z. Its registry update date was 2024-06-14, and PeptideScanner's reviewed identity mapping was abaloparatide.
PeptideScanner retained ClinicalTrials.gov record NCT02927392 at 2026-07-30T18:43:56.185Z. Its registry update date was 2024-06-13, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT03812991 at 2026-11-15T21:54:02.201Z. Its registry update date was 2024-06-11, and PeptideScanner's reviewed identity mapping was calcitonin-salmon.
PubMed lists PMID 23973010 in Thrombosis research as Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2013-08-08 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT05766358 at 2026-07-30T18:43:56.186Z. Its registry update date was 2024-06-10, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT01194271 at 2026-07-30T18:43:56.180Z. Its registry update date was 2024-06-06, and PeptideScanner's reviewed identity mapping was leuprolide.
The official Drugs@FDA dataset lists original submission 1 for NDA 218771 with status AP dated 2024-06-04, and names teriparatide among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT02157974 at 2026-07-30T18:43:56.184Z. Its registry update date was 2024-06-04, and PeptideScanner's reviewed identity mapping was exenatide.
DailyMed lists Structured Product Labeling version 13 for the reviewed Leuprolide label family with a published date of 2024-06-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2024-12065, attributed to FDA and its parent HHS department, on 2024-06-03. Its official title is “Pfizer, Inc., et al.; Withdrawal of Approval of 23 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon.
PubMed lists PMID 38817802 in Drugs in context as Journal Article, with publication-date metadata of 2024-05-20 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38813446 in EClinicalMedicine as Journal Article, with publication-date metadata of 2024-04-11 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT03987451 at 2026-07-30T18:45:10.889Z. Its registry update date was 2024-05-29, and PeptideScanner's reviewed identity mapping was semaglutide.
PubMed lists PMID 38713958 in Journal of colloid and interface science as Journal Article, with publication-date metadata of 2024-04-15 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38784937 in Postepy dermatologii i alergologii as Journal Article, Review, with publication-date metadata of 2024-04-12 (day precision). PeptideScanner associated the retained record with the identity slug afamelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 37548701 in Shock (Augusta, Ga.) as Systematic Review, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-08-07 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 1 for the reviewed Lanreotide label family with a published date of 2024-05-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PubMed lists PMID 28179743 in Hospital pharmacy as Journal Article, with publication-date metadata of 2017-01 (month precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for ANDA 217193 with status AP dated 2024-05-21, and names lanreotide acetate among the application record's active ingredients.
PubMed lists PMID 38533780 in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia as Letter, Review, with publication-date metadata of 2024-03-27 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00089895 at 2026-11-15T21:59:29.646Z. Its registry update date was 2024-05-17, and PeptideScanner's reviewed identity mapping was eptifibatide.
The Federal Register published notice 2024-10896, attributed to FDA and its parent HHS department, on 2024-05-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05027308 at 2026-11-15T21:55:23.600Z. Its registry update date was 2024-05-16, and PeptideScanner's reviewed identity mapping was teduglutide.
PubMed lists PMID 19467157 in Virology journal as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2009-05-25 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 23931055 in Periodontology 2000 as Journal Article, Research Support, N.I.H., Extramural, Review, with publication-date metadata of 2013-10 (month precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38555801 in Asian journal of psychiatry as Letter, with publication-date metadata of 2024-03-19 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213599 with status AP dated 2024-05-09, and names eptifibatide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213988 with status AP dated 2024-05-08, and names vasopressin among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT04909333 at 2026-07-30T18:45:10.887Z. Its registry update date was 2024-05-08, and PeptideScanner's reviewed identity mapping was exenatide.
PubMed lists PMID 23203082 in International journal of molecular sciences as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2012-11-09 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT05046132 at 2026-07-30T18:45:10.886Z. Its registry update date was 2024-05-03, and PeptideScanner's reviewed identity mapping was setmelanotide.
PubMed lists PMID 36656570 in European journal of haematology as Journal Article, Review, with publication-date metadata of 2023-02-12 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for ANDA 217860 with status AP dated 2024-05-02, and names octreotide acetate among the application record's active ingredients.